PURPOSE: The purpose of this workshop is (i) To review current initiatives on digital Pill (ii) To describe potential benefits of digital pill in improving persistence and compliance (iii) To discuss advantage and issues on e-connected medicine in mental health contexts (iv) To formulate future value and challenges of treatment with e-connected medicine. DESCRIPTION: In November 2017, FDA approved the first digital pill with a sensor that digitally tracks if patients have ingested their medication and can tell doctors (or relatives) whether, and when, patients take their medicine. The approval was a significant advance in the expanding field of digital devices designed to monitor medicine-taking and to address the expensive, longstanding problem of compliance and persistence. Several other systems are currently being developed for different therapeutic areas. A recent review estimated that a lack of adherence/compliance/persistence costs the already strained healthcare system between $100–$289 billion a year. In this workshop, the advantages and issues associated with digital pill will be described and how digital pill change the value of pharmaceutical as an introduction of e-connected medicine. Firstly, Dr Toumi will highlight the potential advantage of digital devices from various perspectives including effectiveness and efficiency and consideration in HTA evaluation. Dr. Kishimoto will discuss potential benefit of the digital pill based on his research on non-adherence in schizophrenia and the effectiveness of long acting injectable antipsychotics. Dr. Igarashi will discuss the potential implications for the treatment environment and the impact on the Japanese health care system from HTA perspectives. Ms. Aitoku will draw the value and expectation ,and challenges in future treatment paradigm beyond the pill.